Alkem Laboratories Ltd. - Research Center
539523 ALKEM Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 4,887.76 | 4,519.84 | 4,187.15 | 4,642.66 | 3,534.95 |
| Operating profit | 988.35 | 588.99 | 671.95 | 1,138.41 | 1,100.84 |
| Interest | 40.12 | 42.04 | 20.34 | 17.56 | 26.80 |
| Gross profit | 1,074.77 | 675.90 | 769.08 | 1,203.27 | 1,131.33 |
| EPS (Rs) | 76.78 | 41.05 | 42.99 | 85.93 | 77.07 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 126.54 | 128.95 | 117.47 | 82.42 | 57.29 |
| Stock adjustment | -52.57 | 251.15 | -289.69 | -71.21 | -73.85 |
| Raw material | 1,396.49 | 1,282.12 | 1,499.19 | 1,350.56 | 857.94 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 809.24 | 800.00 | 670.76 | 763.73 | 579.56 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,746.25 | 1,597.58 | 1,634.94 | 1,461.17 | 1,070.46 |
| Provisions made | - | - | - | - | - |
| Depreciation | 117.13 | 114.55 | 113.44 | 105.54 | 99.47 |
| Taxation | 39.69 | 70.56 | 141.67 | 70.45 | 110.50 |
| Net profit / loss | 917.95 | 490.79 | 513.97 | 1,027.28 | 921.36 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 20.22 | 13.03 | 16.05 | 24.52 | 31.14 |
| GPM (%) | 21.43 | 14.54 | 17.87 | 25.47 | 31.49 |
| NPM (%) | 18.31 | 10.56 | 11.94 | 21.74 | 25.65 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis